Inventor · disambiguated record
Hans Briem
Also filed as: BRIEM HANS
51 granted patents·31 pending applications·447 citations·filing 1995–2021
98Inventor score
Files withBayer Pharma AG29BOEHRINGER INGELHEIM KG13BOEHRINGER INGELHEIM PHARMA8BAYER SCHERING PHARMA AG7BAYER IP GMBH5
Top patents by PatentIndex Score
82 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0293US7166599B2Trisubstituted pyrimidinesBOEHRINGER INGELHEIM PHARMA·Filed 2004·Granted Jan 23, 2007·54 cites·7 claims
- 0392US7312225B2Macrocyclic pyrimidines, their production and use as pharmaceutical agentsBAYER SCHERING PHARMA AG·Filed 2003·Granted Dec 25, 2007·73 cites·9 claims
- 0489US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0588US6191135B1Neurokinin antagonistsBOEHRINGER INGELHEIM KG·Filed 2000·Granted Feb 20, 2001·25 cites·9 claims
- 0685US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0785US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 0884US5710155AArylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compoundsBOEHRINGER INGELHEIM KG·Filed 1996·Granted Jan 20, 1998·26 cites·10 claims
- 0982US5708006ANeurokinin antagonistsBOEHRINGER INGELHEIM KG·Filed 1995·Granted Jan 13, 1998·29 cites·4 claims
- 1081US7825128B2Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugsBAYER SCHERING PHARMA AG·Filed 2006·Granted Nov 2, 2010·7 cites·18 claims
- 1180US9670202B2Substituted triazolopyridinesBayer Pharma AG·Filed 2014·Granted Jun 6, 2017·2 cites·16 claims
- 1279US6512000B1Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activityBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jan 28, 2003·11 cites·17 claims
- 1378US10266548B2Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2017·Granted Apr 23, 2019·2 cites·2 claims
- 1478US9643953B2Substituted benzylpyrazolesBAYER IP GMBH·Filed 2012·Granted May 9, 2017·5 cites·10 claims
- 1578US7846928B2Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of sameBAYER SCHERING PHARMA AG·Filed 2007·Granted Dec 7, 2010·4 cites·39 claims
- 1678US7504410B2Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agentsSCHERING AG·Filed 2003·Granted Mar 17, 2009·13 cites·22 claims
- 1777US10428063B24H-pyrrolo[3,2-C]pyridin-4-one derivativesBayer Pharma AG·Filed 2016·Granted Oct 1, 2019·3 cites·15 claims
- 1877US9682974B2Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Granted Jun 20, 2017·4 cites·8 claims
- 1977US5861509AArylglycinamide derivatives and pharmaceutical compositions containing these compoundsBOEHRINGER INGELHEIM KG·Filed 1997·Granted Jan 19, 1999·16 cites·12 claims
- 2077US5696123ANeurokinin antagonistsBOEHRINGER INGELHEIM KG·Filed 1995·Granted Dec 9, 1997·33 cites·4 claims
- 2176US5985881ANeurokinin antagonistsBOEHRINGER INGELHEIM KG·Filed 1997·Granted Nov 16, 1999·28 cites·14 claims
- 2275US9745285B2Heteroaryl substituted pyrazolesBayer Pharma AG·Filed 2014·Granted Aug 29, 2017·3 cites·5 claims
- 2375US6235732B1Neurokinin antagonistsBOEHRINGER INGELHEIM KG·Filed 1999·Granted May 22, 2001·27 cites·17 claims
- 2474US9765058B2Substituted benzylpyrazolesBayer Pharma AG·Filed 2014·Granted Sep 19, 2017·3 cites·14 claims
- 2574US6365584B1Arylysulphonamide-substituted benzimidazoles having tryptase-inhibiting activityBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Apr 2, 2002·7 cites·17 claims
- 2674US6294556B1Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compoundsBOEHRINGER INGELHEIM KG·Filed 2000·Granted Sep 25, 2001·5 cites·38 claims
- 2770US7795264B2Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of sameBAYER SCHERING PHARMA AG·Filed 2007·Granted Sep 14, 2010·1 cites·23 claims
- 2870US6407130B1Carboxamide-substituted benzimidazoles having tryptase-inhibiting activityBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jun 18, 2002·5 cites·18 claims
- 2970US6251909B1Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compoundsBOEHRINGER INGELHEIM KG·Filed 2000·Granted Jun 26, 2001·3 cites·32 claims
- 3068US6514969B2β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositionsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Feb 4, 2003·6 cites·16 claims
- 3167US9206185B2Imidazopyridazines as Akt kinase inhibitorsBärfacker Lars·Filed 2012·Granted Dec 8, 2015·2 cites·39 claims
- 3266US10350206B2Benzyl substituted indazoles as BUB1 inhibitorsBayer Pharma AG·Filed 2015·Granted Jul 16, 2019·1 cites·28 claims
- 3365US6303601B2Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compoundsBOEHRINGER INGELHEIM KG·Filed 2001·Granted Oct 16, 2001·1 cites·48 claims
- 3464US10604532B2Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2019·Granted Mar 31, 2020·0 cites·6 claims
- 3563US8551980B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Oct 8, 2013·1 cites·13 claims
- 3662US6245777B1N-(5-phenyl-tetrahydrofuranyl)methyl- and N-(6-phenyl-tetrahydropyranyl)methyl-substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-olsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jun 12, 2001·2 cites·20 claims
- 3761US6413990B1Arylsulphonamide-substituted benzimidazoles having tryptase-inhibiting activityBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jul 2, 2002·2 cites·12 claims
- 3861US2016046604A1Heteroaryl substituted indazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 3959US6413959B1Method of treating depression with arylglycinamide derivativesBOEHRINGER INGELHEIM KG·Filed 2001·Granted Jul 2, 2002·1 cites·85 claims
- 4059US2016052912A1Diaminoheteroaryl substituted indazolesBAYER PHARMA AKITIENGESELLSCHAFT·Filed 2014·Application pending·0 cites
- 4153US2017275267A1Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancerBayer Pharma AG·Filed 2017·Application pending·0 cites
- 4253US2023357239A1Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitorsBAYER AG·Filed 2021·Application pending·0 cites
- 4352US6124296AArylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compoundsBOEHRINGER INGELHEIM KG·Filed 1996·Granted Sep 26, 2000·6 cites·22 claims
- 4452US6121262AArylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compoundsBOEHRINGER INGELHEIM KG·Filed 1999·Granted Sep 19, 2000·3 cites·7 claims
- 4552US2014249133A1Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 4651US2016046610A13-heteroaryl substituted indazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4751US2017283396A1Diaminoheteroaryl substituted indazolesBayer Pharma AG·Filed 2017·Application pending·0 cites
- 4848US8481539B2Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of sameHARTUNG INGO·Filed 2008·Granted Jul 9, 2013·0 cites·9 claims
- 4948US2023072421A1Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancerBAYER AS·Filed 2020·Application pending·0 cites
- 5048US2015141372A1Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancerBayer Pharma AG·Filed 2013·Application pending·0 cites
Showing the top 50 of 82 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hans Briem files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →